[Weekly paclitaxel infusion in patients with recurrent ovarian cancer--a pilot study].
This preliminary study was performed to evaluate the safety and efficacy of weekly paclitaxel administration by 1-hour infusion. A total of 7 patients with recurrent ovarian cancer were treated with weekly paclitaxel (TXL). TXL was given at a dose of 70 mg/m2 in 1-hour infusions every week for at least 20 consecutive weeks unless lesions became progressive. Premedication was administered 30 min before TXL infusion. The 7 patients received a total 110 cycles of therapy. Hypersensitivity reactions were not observed. Grade 3 or 4 neutropenia occurred in only 0.9% of the cycles. Neurotoxicity was commonly observed, but that of grade 3 or greater severity was not recorded. No other severe non-hematologic toxicities were observed. Partial responses were seen in three of 7 patients. Weekly 1-hour TXL is considered to be safe and effective as a salvage therapy in patients with recurrent ovarian cancer.
Kawagoe
Hidehiro
H
Dept. of Obstetrics and Gynecology, Kumamoto City Hospital.
Kawata
Takanobu
T
Nishio
Shin
S
Shimomura
Takuya
T
Fujiyoshi
Keizou
K
Ishimatsu
Junji
J
Tsunawaki
Akitsu
A
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011788:Quality of Life
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel